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Mycotic abdominal aortic aneurysms (MAAAs) are rare
entities accounting for 0.65–2% of aortic aneurysms.
Campylobacter fetus has a tropism for vascular tissue
and is a rare cause of mycotic aneurysm. We present a
73-year-old male patient with contained rupture of a
MAAA caused by C. fetus, successfully treated with
endovascular aortic repair (EVAR) and antibiotics, which
is not previously described for this aetiology. Although
open surgery is the gold standard, EVAR is nowadays
feasible and potentially represents a durable option,
especially in frail patients.
BACKGROUND
The natural history of a mycotic abdominal aortic
aneurysm (MAAA) is that of a rapid progression to
rupture and usually death.1 2 Campylobacter fetus
is an actual infective agent for MAAA, especially in
elderly or debilitated patients.3 4 We report here
the ﬁrst case efﬁciently treated by endovascular
aortic repair (EVAR) and antibiotic therapy. In frail
patients, EVAR could be a suitable alternative,
allowing immediate less invasive treatment. Even if
it is generally considered a bridge therapy, it could
also sometimes represent a more durable treatment
option with total remission of the infection.
CASE PRESENTATION
A 73-year-old male patient presented to our emer-
gency department after 4 days of fever, chills and
pain in the lower abdomen irradiating to the back.
He also reported having diarrhoea for 3 days.
Medical history was relevant for ischaemic and
hypertensive heart disease. Seven days previously
he had a coronarography. He had a temperature of
37.8°C, normal blood pressure and heart rate and
abdominal pain without signs of peritonitis. No
pulsatile abdominal mass was palpable.
INVESTIGATIONS
Blood tests showed an elevated white cell count of
15.5 G/L (normal value: 4–10 G/L), an elevated C
reactive protein of 315 mg/L (normal value<5 mg/L)
and a haemoglobin value of 105 g/L (normal value:
120–180 g/L). An abdominal CT scan showed a par-
tially thrombosed infrarenal atherosclerotic aortic
aneurysm of 38 mm with periaortitis (ﬁgure 1).
A CT scan performed the next day because of wor-
sening abdominal pain showed a contained rupture
(ﬁgure 2A, B). Blood cultures were positive for
C. fetus.
DIFFERENTIAL DIAGNOSIS
Contained rupture of a MAAA following infectious
aortitis was the main diagnostic hypothesis. The
hypothesis of a postcoronarography aneurysmal
infection was invalidated by the blood cultures
showing C. fetus, no cutaneous germs and by the
absence of previous aneurysmal disease.
TREATMENT
Intravenous empiric antibiotic treatment with
amoxicilline–clavulanate was initiated immediately
after the ﬁrst abdominal CT scan, and the patient
was admitted to the intensive care unit. He was
operated 24 hours later after clinical deterioration
and a CT scan showing a contained rupture of the
aneurism. He was considered unﬁt for open surgery
because of severe ischaemic heart disease. A ‘bridge
therapy’ with EVAR was therefore planned. He
underwent a percutaneous endovascular aneurysmal
Figure 1 Abdominal CT scan showing an infrarenal
atheroscleroting aortic aneurysm of 38 mm with
periaortitis.
Figure 2 (A and B) CT scan performed the second day
because of acute abdominal pain showing signs of
contained rupture.
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exclusion with endograft (Endurant II ETLW 16×16 C 93 and
ETLW 16×16 C 82) under local anaesthesia. After blood cultures
were found to be positive for C. fetus, the initial antibiotic
therapy was replaced by an intravenous treatment with imipe-
nem–cilastatin for 3 weeks followed by oral ciproﬂoxacin for
3 weeks.
OUTCOME AND FOLLOW-UP
Our patient had a favourable postoperative outcome. An
abdominal CT scan on postoperative day 3 showed exclusion of
the aneurysm by the endoprosthesis. A small type II endoleak
required no speciﬁc treatment. The patient was discharged
9 days after surgery and followed up regularly. At 12 months,
the clinical evolution was favourable. The clinical examination
and CT scan showed no endoleak or signs of infection, so it was
decided not to convert to open surgery.
DISCUSSION
The entity of mycotic aneurysm was ﬁrst described by William
Osler in 1885.2 The term is, however, misleading since the
majority of mycotic aneurysms are due to bacterial infection
and are not fungal in nature. Since the classical triad of fever,
abdominal pain and pulsatile abdominal mass is not always
present, the diagnosis of a mycotic aneurysm can be very chal-
lenging and requires a high degree of suspicion.3 4 The most
commonly cultured organisms include Staphylococcus (30%),
Streptococcus (10%) and Salmonella (10%).1–4 Other
microorganisms such as Brucella can be responsible for aortitis.5
C. fetus is a very rare cause of mycotic aneurysm especially in
the elderly with other underlying pathologies.3 In our case, the
patient was an elderly ex-smoker with ischaemic heart disease
and a recent history of gastroenteritis. He was not known for
having an abdominal aortic aneurysm. During hospitalisation,
he had no gastrointestinal symptoms and stool cultures that
could have shown that he was an asymptomatic germ carrier
were unfortunately not performed. The fact that the blood cul-
tures were positive for C. fetus indicates that the patient had in
all probability ﬁrst suffered from bacteraemia with C. fetus,
which led to an aortits that itself degenerated into a mycotic
aneurysm. Regarding the treatment of MAAA, antibiotic
therapy is essential but is inadequate if given alone.3 6–9 The
appropriate dose, duration and regimen of antibiotic therapy
have not yet been established. Some authors report that a
period of 4–8 weeks of antibiotic treatment is sufﬁcient,
whereas others insist on lifelong antibiotic therapy.1 3 There is
no widely accepted consensus on this point, and the indications
must therefore be determined case by case. Surgical intervention
for MAAA remains challenging. Extra-anatomic bypass has been
replaced9 by in situ graft replacement surgery as the gold stand-
ard treatment.4 10 EVAR has been introduced as an alternative
allowing minimally invasive intervention with prompt aneurys-
mal exclusion and immediate control of bleeding. It is particu-
larly useful in the case of severely ill or elderly patients. Until
recently, EVAR was considered to be a temporary treatment
Table 1 A summary of mycotic abdominal aneurysms caused by Campylobacter fetus
Author Year Antibiotic therapy Operation Outcome
Dolev et al6 1971 – Replaced-Dacron graft Died few hours after operation
File et al7 1979 – – Died before operation
Taylor et al8 1979 – – Died before operation
Anolik et al9 1983 Long term Aneurysm excision, AXBF Alive, 45 months
Marty et al10 1983 7 months Replaced-Dacron graft Alive, 2 years
Blabey et al11 1983 7 weeks Aneurysm excision, AXBF Alive, 18 months
Righter Woods12 1985 1 week Replaced-Dacron graft Alive, 3 years
Perry13 1985 8 weeks Replaced-Dacron graft Alive, 6 months
Rutherford et al14 1989 5 months Dacron graft Alive, 2 years
Jacobs et al15 1989 – Aneurysm excision, AXBF Died after 7 days
Kato et al16 1990 2 weeks Aneurysm excision, AXBF Alive, 36 months
Allerberger et al17 1991 – – Died, before operation
Grollier et al18 1993 – Replaced-Dacron graft ND
Mii et al19 1998 3 months Replaced-Dacron graft Alive, 1 year
Tran et al20 2007 Life long Replaced-Polyester graft Alive, 9 months
Cochennec et al21 2008 Long term Replaced-Dacron graft Alive, 6 months
Cochennec et al21 2008 Long term Dacron graft Alive, 5 months
Cochennec et al21 2008 Long term EVAR Died, after 2 weeks
Cochennec et al21 2008 Long term Replaced-Allograft Alive, 18 months
Brossier et al22 2010 – Replaced-Dacron graft Alive, 34 months
Brossier et al22 2010 – Replaced- Silver graft Alive, 28 months
Brossier et al22 – Replaced-Dacron graft Alive, 5 months
Brossier et al22 2010 – EVAR Died, after 15 days
Brossier et al22 2010 – Replaced-Allograft Alive, 38 months
Maeda et al1 2011 – Replaced-Polyester graft Alive
Maeda et al1 2011 – Replaced-Polyester graft Alive
Noda et al23 2011 More than 4 weeks Replaced-Dacron graft Alive, 1 year
Hagiya et al24 2013 Long term Replaced-Polyester J graft Alive, 1 year
Present case 2015 6 weeks EVAR (Endurant II stent graft) Alive, 1 year
AXBF, axillobifemoral bypass operation; EVAR, endovascular aortic repair.
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prior to deﬁnitive open repair and was therefore called a ‘bridge
to open surgery’.2 However, a recent study comparing the
results of EVAR with those of conventional surgery for treat-
ment of MAAA showed that EVAR appears to be equivalent to
surgery.4 Additionally, the European multicentre collaboration
trial, the largest ever on mycotic aortic aneurysm, studied the
durability of EVAR by assessing late infection-related complica-
tions and long-term survival. The study concludes that EVAR
can be a durable treatment option for most patients. Open
repair shows short-term mortality rates of 20–40% and signiﬁ-
cant short-term and long-term morbidities related to the oper-
ation with a 5-year survival of 35%.2 According to the same
study, EVAR has a good short-term outcome with 91% survival
at 30 days and 55% at 5 years. However, the implantation of
prosthetic material in an infected site remains a major problem.
The study shows 19% of fatal infection-related complications,
mostly occurring during the ﬁrst postoperative year for EVAR,
versus only 7–10% for open surgery. Non-Salmonella-positive
blood cultures seem to be the main factor associated with
serious late infectious complications.2 Long-term antibiotic
treatment and strict follow-up are required in order to minimise
late infections that are often fatal. Our patient was successfully
treated with EVAR and 6 weeks of antibiotics. At 1 year, he
showed no signs of infectious complications. To the best of our
knowledge, this is the 29th case of MAAA infected with C. fetus
to be reported in the English literature and the ﬁrst case to be
successfully treated with EVAR (table 1).1 6–24
Learning points
▸ Mycotic aneurysms are rare, regardless of aetiology, and
should be suspected when symptoms and patient
characteristics make it an actual differential diagnosis.
In such circumstances, a CT scan and blood cultures are
mandatory.
▸ Ideal duration of antibiotic treatment has not yet been
established. In our case, 6 weeks seem to have been
sufﬁcient; however, follow-up is probably too short for ﬁnal
conclusions.
▸ This case supports the use of EVAR in patients with mycotic
aneurysms with Campylobacter fetus, even though earlier
attempts of EVAR in similar cases failed.
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